Abstract | OBJECTIVE: METHOD: RESULT: Six trials in 4 studies that compared instillation of OBTX-A and placebo involving 248 patients (121 experimental and 127 controls) were included for final data extraction. Instillation of OBTX-A significantly increased VV, with a mean difference of 38.48 (95% confidence interval: 76.05, 0.92) compared to the placebo group. However, other outcomes showed statistically insignificant changes. Major adverse events were not reported in the group receiving intravesical instillation of OBTX-A. CONCLUSION:
|
Authors | Hyun Young Lee, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Hwa Yeon Sun, Eli Jongchan Nho, Bora Lee, Jae Heon Kim |
Journal | Urology
(Urology)
Vol. 125
Pg. 50-57
(03 2019)
ISSN: 1527-9995 [Electronic] United States |
PMID | 30552935
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
|
Copyright | Copyright © 2018 Elsevier Inc. All rights reserved. |
Chemical References |
- Botulinum Toxins, Type A
- onabotulinum toxin A
|
Topics |
- Administration, Intravesical
- Botulinum Toxins, Type A
(administration & dosage)
- Cystitis, Interstitial
(drug therapy)
- Humans
- Treatment Outcome
- Urinary Bladder, Overactive
(drug therapy)
|